Details of the Drug

General Information of Drug (ID: DMWTVAN)

• Drug Name: RAUWOLFIA SERPENTINA ROOT
• Synonyms: Raubasine; 483-04-5; Ajmalicin; Circolene; Sarpan; py-Tetrahydroserpentine; Tetrahydroserpentine; UNII-4QJL8OX71Z; EINECS 207-589-5; BRN 0097268; 4QJL8OX71Z; CHEBI:2524; CHEMBL123325; Methyl 16,17-didehydro-19alpha-methyl-18-oxayohimban-16-carboxylat; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid m

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Approved	[1]

• Drug Type: Small molecular drug
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2.098 +/- 0.441 mg/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.042 +/- 0.80 h [2]
  Bioavailability: The bioavailability of drug is 64% [2]
  Clearance: The drug is cleared by the liver and kidneys [3]
  Elimination: The elimination of reserpine and its metabolites in the feces ranges from 30% after intramuscular administration to about 60% after oral ingestion, primarily as unmetabolized reserpine, over a 4 day period after the ingestionof 0.25 mg to 0.50 mg doses [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5 hours [4]
  Metabolism: The drug is metabolized via the hepatic [5]
• Cross-matching ID:
  DrugBank ID: DB09363
  TTD ID: D0U7GP
  VARIDT ID: DR01047

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)	TTZIFHC	CAC1C_HUMAN	Inhibitor	[1]

References

• [1] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [2] Bolton GC, Allen GD, Davies BE, Filer CW, Jeffery DJ: The disposition of clavulanic acid in man. Xenobiotica. 1986 Sep;16(9):853-63. doi: 10.3109/00498258609038967.
• [3] Reserpine
• [4] Reserpine, Drugs.com
• [5] Reserpine